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Abstract
Background: BRCA mutation carriers have a 40-80% life-time risk of developing breast cancer. They may opt for
yearly breast cancer surveillance or for prophylactic mastectomy. Both options show increased survival rates. It is a
complex choice to be made between these two options. As a result most women experience high levels of
distress and high needs for information. To fulfill the needs for psychosocial support and information we have
introduced group medical consultations (GMCs). A GMC provides individual medical visits conducted within a
group. This 90 minute group-visit with 8-12 patients gives patients the opportunity to spend more time with their
clinician and a behavioral health professional and learn from other patients experiencing similar topics. However, it
should be noted that group sessions may increase fear in some patients or influence their decision making.
Methods/design: In this randomized controlled trial, 160 BRCA mutation carriers diagnosed maximally 2 years ago
are recruited from the Radboud University Nijmegen Medical Centre. Participants are randomized in a 1:1 ratio to
either the GMC intervention group (onetime participation in a GMC instead of a standard individual visit) or to a
usual care control group. Primary outcome measures are empowerment and psychological distress (SCL 90).
Secondary outcome measures are fear of cancer, information needs before the consultation and the received
information, self-examination of the breasts, patient satisfaction, quality of life and cost-effectiveness. Data are
collected via self-reported questionnaires 1 week before the visit, and at 1 week and at 3 months follow-up. A pilot
study was conducted to test all procedures and questionnaires.
Discussion: The possibility for interaction with other BRCA mutation carriers within a medical visit is unique. This
study will assess the effectiveness of GMCs for BRCA mutation carriers to improve empowerment and decrease
distress compared to individual visits. If GMCs prove to be effective and efficient, implementation of GMCs in
regular care for BRCA mutation carriers will be recommended.
Trial registration: The study is registered at ClinicalTrials.gov (NCT01329068)
Background
BRCA mutation carriers have a high life-time risk of devel-
oping breast cancer and also of ovarian cancer. In a large
meta-analysis of ten studies the mean cumulative breast
cancer risk at 70 years was 46-80% for BRCA1 mutation
carriers and 40-80% for BRCA2 mutation carriers [1-3].
Because of this high risk of breast cancer, women with a
mutation in either the BRCA1 or BRCA2 gene are offered
breast cancer surveillance, which includes annual clinical
breast examination, annual mammography and annual
contrast enhanced magnetic resonance imaging (MRI) of
the breast [4-6]. Alternatively, women may opt for prophy-
lactic bilateral mastectomy with or without breast recon-
struction [7-10]. Prophylactic bilateral mastectomy
reduces the risk for breast cancer by 89.5-100%[11], mak-
ing yearly surveillance unnecessary. Although prophylactic
mastectomy minimizes the risk of breast cancer, compar-
able survival rates are seen for prophylactic mastectomy
and yearly breast cancer surveillance [10].
BRCA mutation carriers who underwent treatment for
breast cancer before, have to deal with a 50-64% lifetime
risk for developing a second primary breast cancer [12].
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Most studies among BRCA mutation carriers who had
breast cancer have shown a reduction in the risk of con-
tralateral breast cancer, while results on survival rates
were diverse [10,13-15]. Besides, the decision for con-
tralateral prophylactic mastectomy depends on age, type
of initial breast cancer surgery, prophylactic oophorect-
omy and the patient’s opinion [16].
Thus, BRCA mutation carriers face a complex choice
between these options. The knowledge of BRCA carrier-
ship and the consequently increased risk of developing
breast (and ovarian) cancer may have a large psychosocial
impact on mutation carriers. The level of cancer related
distress among Jewish women increased significantly after
the diagnosis of a BRCA mutation [17]. In another study
36 percent of women diagnosed with a BRCA1 mutation
appeared to be sad or crying [18]. Several studies in the
Netherlands showed that genetic testing, regardless of the
test results may already increase levels of distress [19,20].
The provision of psychosocial support is intrinsically
connected to the provision of guidance in the choice
between surveillance and a prophylactic mastectomy. In a
study of 233 women who were awaiting their initial
appointments for risk assessment, consideration of pro-
phylactic mastectomy strongly correlated with high levels
of breast cancer anxiety and overestimation of one’s breast
cancer risk, whereas there was no association with objec-
tive breast cancer risk [21]. Recently, it was suggested that
standard visit with a psychologist for high-risk women
considering prophylactic mastectomy may be indicated
since anxiety is one of the main reasons for considering a
prophylactic mastectomy, and depression and grief were
present in a third of the participating women [22]. Inter-
estingly, in this study uncertainty about surgery and the
need for further information were the reasons given most
frequently for postponing prophylactic mastectomy, indi-
cating that there is a great need for information in this
group [23]. Generally, the decision about surveillance or
prophylactic mastectomy is not a medically urgent one
and women can indeed take time to gather and process all
information and talk about it with others. Of note, patient
satisfaction is an important predictor of quality of life,
treatment compliance and lower rates of anxiety and
depression [24]. In previous studies it has been shown that
in order to improve the patient satisfaction it is important
for the clinician to discuss psychosocial factors and to be
responsive to the patients concerns [25,26].
To fulfill the needs just mentioned concerning psycho-
social support and information we have introduced
group medical consultations (GMCs) for the surveillance
of BRCA mutation carriers. A GMC provides individual
medical visits conducted within a group, giving patients
the opportunity to spend more time with their own clin-
ician in the setting of a support group with a behavioral
health professional and learn from other patients experi-
encing similar topics. In contrast to the typical 15-20-
minute office visit, a 90-minute group-visit with 8-12
patients permits ample time for discussion and educa-
tion. The incorporation of the individual medical visit in
a GMC distinguishes GMCs from educational work-
shops and support- and self-management groups. In
general, the group of patients in a GMC is composed of
different participants from meeting to meeting. Cur-
rently, GMCs have been offered to patients of different
ages with a variety of diseases [27,28]. Although several
benefits of GMCs compared to individual visits have
been reported, the effects have not been evaluated for
the surveillance of BRCA mutation carriers.
Most previous studies showed improved satisfaction in
patients receiving GMCs and in health professionals pro-
viding GMCs. The unhurriedness of the clinician and the
time spent with the clinician is appreciated most by
patients [29-33]. Clinicians were positive about the inno-
vative and multidisciplinary working method [34].
Besides improved quality of life, which is reported in sev-
eral studies [32,35,36], also improved health behavior,
self-efficacy for following certain health promoting inter-
ventions and knowledge of the disease was shown among
diabetes patients and patients with coronary artery dis-
ease who participated in a group visit [35,37]. Also, qual-
ity of care is improved. For example, in a study of
diabetic patients group visit participation was positively
associated with patients receiving preventive procedures,
review of medication and microalbuminuria test recorded
in the registry [38]. Other studies in diabetic patients
have confirmed these results [31,39-41]. When planned
carefully, this type of visits may increase clinician satis-
faction and productivity [30,36,42-44].
However, it should be noted that group sessions may
not be beneficial [45]. Recently the effects of educational-
support groups for BRCA mutation carriers have been
studied [46]. This program included eight sessions with
alternately a psychosocial (5 sessions) and a medical
information focus (3 sessions); no individual visits were
provided in the group. The study provided presumptive
evidence that educational-support group participants
were more inclined to undergo prophylactic mastectomy
than non-participants. Possibly the occurrence of group
members getting cancer during surveillance affected
other group members. Group participation may have
triggered feelings of anticipated regret, i.e. regret that
women think they would have if they were to be diag-
nosed with breast cancer after not (yet) having chosen
the option of prophylactic mastectomy [47]. Therefore,
before introducing GMCs in regular patient care for
BRCA mutation carriers the pros and cons of GMCs for
this population should carefully be evaluated.
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Methods/Design
Design
The study examines the effect of GMCs on patient
empowerment and psychological distress of BRCA
mutation carriers as well as several secondary outcome
measures. This randomized controlled trial (RCT) will
compare two groups; the intervention group, who will
participate in a GMC once and the control group, who
will receive care as usual (surveillance in an individual
visit).
Ethical consideration
The study has been approved by the medical ethical
committee of the Radboud University Nijmegen Medical
Centre. Full medical ethical approval has been obtained
in February 2011.
Study sample
A total of 160 recently diagnosed BRCA mutation car-
riers will be invited to participate in the study. To sti-
mulate interaction and discussion within the group it is
important to compose heterogeneous groups. Neverthe-
less, some homogeneity is needed to keep the GMCs
relevant for everyone [34]. Therefore the following in-
and exclusion criteria were formulated. Inclusion criteria
are: carrier of a BRCA1 or a BRCA2 mutation; diag-
nosed maximally 2 years ago; and a minimum age of 25.
Exclusion criteria are: currently involved in a diagnostic
work-up because of a suspicion of breast cancer, either
primary or metastatic; a history of prophylactic mastect-
omy or current psychiatric disease precluding visits in a
group; insufficient command of the Dutch language to
be able to follow a group discussion and fill out ques-
tionnaires in Dutch.
Recruitment and randomization
Women with the BRCA mutation having their yearly
surveillance in the Radboud University Nijmegen Medi-
cal Centre will be informed about the study during an
individual visit to the outpatient clinic or approached
via a telephone call by the researcher. As shown in
Figure 1 patients will be randomized for their next visit
Figure 1 Flow-chart of the study.
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to either the intervention group (GMC) or the control
group (individual visit) after informed consent is
obtained. Randomization will take place per patient in a
1:1 ration and in blocks of 16 patients. The individual
clinician, will meet the same number of patients in a
GMC and in an individual consultation, therefore we
pre-stratified for clinician.
Intervention
Patients randomized to the intervention group will partici-
pate once in a GMC instead of a standard individual visit.
The GMC will provide individual medical visits conducted
within a group, giving patients the opportunity to spend
more time with their own clinician in the setting of a sup-
port group. In this way patients can learn from other
patient’s experiences with similar topics. A social worker
will be present during every GMC. Besides leading the dis-
cussion and making sure every patient receives equal
attention from the clinician, the social worker will be avail-
able for psychosocial related questions and support. The
group visit itself will take 90 minutes. In advance, half an
hour will be scheduled for physical examination, where
privacy concerns will be taken into account. The control
group will have their usual individual visit with the clini-
cian. The clinician and the social worker will both use pro-
tocols with information based on most up-to-date
publications concerning BRCA gene mutation related
topics, specially developed for the GMCs.
Study outcomes
At baseline, 1 week after and 3 months after the (group or
individual) visit participants will be asked to fill out a ques-
tionnaire. Patients refusing participation will be asked to
fill out one questionnaire to gain insight in reasons for not
participating. Demographical data will be collected as well
as the following measures.
Primary outcome measures
Empowerment is the first primary outcome, which will
be measured using the Empowerment Questionnaire for
breast cancer patients. This questionnaire has been
developed and validated in the Netherlands for the
assessment of empowerment in psychiatric patients.
With minor revisions, the 40-item questionnaire was
validated in breast cancer survivors. The study involved
140 non-metastatic breast cancer patients who were
treated in the past with curative intent. Four factors
were extracted, explaining 53 percent of the total var-
iance. Factor 1 was labeled ‘Personal Strength’, factor 2
‘Social support’, factor 3 ‘Community’ and at least factor
4 ‘Health Care’. The internal consistency reliability for
each factor demonstrated good reliability for all four fac-
tors and for the total empowerment scale (alpha = .94)
[48].
Another primary outcome is psychological distress
measured by the Symptom Checklist-90 (SCL-90). SCL-
90 is designed to evaluate a broad range of psychological
problems and symptoms of psychopathology. It can be
used for measuring the progress and outcome of psy-
chiatric and psychological treatments [45,49]. It consists
of 90 items, yielding nine scores along primary symptom
dimensions and three scores among global distress
indices. A countless number of studies demonstrated
the reliability, validity and utility of the instrument.
Secondary outcome measures
Besides the primary outcomes, the following secondary
outcomes are measured. The Cancer Worry Scale will
be used to assess the fear of cancer. It consists of 8
items and is used in several studies among cancer
patients. The internal consistency is good (alpha = .80)
[50,51].
The information needs before the consultation and the
actually received information after the consultation will
be measured by a list of relevant topics for BRCA muta-
tion carriers, including topics like prophylactic mastect-
omy, use of oral contraceptives, depressed mood.
Participants can also add their own topics. In advance of
the visit participant are asked to fill out which topics they
want to discuss during the consultation. One week after
the visit participants will indicate on the topic list which
topics have actually been discussed.
Self-examination of the breasts will be measured by a
question about the frequency of self-examination and
about the reason not to examine their own breasts. One
question is included to assess the patient’s choice for a
prophylactic mastectomy or surveillance.
To assess the patient satisfaction a combination of the
QUOTE questionnaire [52] and some GMC specific
questions will be used [34]. Overall satisfaction with the
visit will be rated on a scale from 1 (not satisfied at all)
to 5 (very satisfied).
The quality of life will be measured by the EORTC-
Q30 and the EORTC-BR23. The EORTC-Q30 is a
health-related quality of life questionnaire which is vali-
dated for oncological clinical research [53]. Chronbach’s
alpha was close to or higher than 0.70 for seven of the
nine scales and ranged between 0.19-0.92 [54]. The ques-
tionnaire consists of 30 items, including a functional,
symptom and health-related quality of life subscale. The
EORTC-BR23 is a validated breast cancer-specific ques-
tionnaire [55,56]. The questionnaire consists of 23 items,
including side effects of therapy, body image, sexuality
and outlook for the future.
To evaluate the cost-effectiveness of the intervention
costs will be measured by several questions from the
Trimbos/iMTA questionnaire for Costs associated with
Psychiatric Illness (TiC-P). This is a frequently used
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instrument for economic evaluations in mental health
care [57].
The researcher will be present during the GMC for
measuring the time spend per patient. This measure will
be used in the analyses to test the relation between time
spend per patient and the effectiveness of the GMC.
Besides, topics discussed during the visits will be mea-
sured by the researcher.
Power calculations
The primary aim of GMCs is to increase patient empower-
ment and to prevent an increase of psychological distress.
Data on these outcome measures for BRCA mutation car-
riers are not yet available, therefore data from a rather
comparable population, breast cancer patients, is used for
the power analysis. Also, data of the SCL-90 is more wide-
spread compared to empowerment data for breast cancer
patients, therefore results of this questionnaire have been
used. A healthy score on the SCL-90 ranges between 90-
130, while breast cancer patients, one year or longer after
curative treatment for breast cancer, achieved an average
score of 138.5 [58]. In this study we strive for a high nor-
mal average score of 125. This implies that an average dif-
ference of 13.5 points can be defined as clinically relevant.
The standard deviation is 45, which is based on three
norm groups [49]. To assess a clinically relevant effect of
GMC on psychological distress with a power of 80%, a
two-side significance of 5%, a standard deviation of 45 and
an expected drop-out of 15%, 80 patients need to be
included in each group.
Statistical analysis
For the primary analysis a covariance analysis
(ANCOVA) will be conducted. Differences in empower-
ment and SCL-90 scores (primary outcome measures) at
baseline and one week after the GMC between the
intervention group and control group will be compared.
In addition ANCOVA provides the opportunity to com-
pare trends over time between the two groups. The
SCL-90 scores at T1 or T2 will be included as depen-
dent variables and the group (individual consult or
GMC) as independent variable. Furthermore, the SCL-
90 score at baseline will be a covariate. The analysis of
the secondary outcome measures is a repeated measure-
ment analysis (ANOVA or mixed model) to compare
trends over time between the two groups.
Cost-effectiveness analyses
Beside effectiveness of the intervention, another impor-
tant measure is the cost-effectiveness. This study will
compare the difference in total costs for health care and
production losses between the intervention group and
the control group. These costs will be estimated by sev-
eral questions. The total direct medical costs (for
example outpatient visits, length of stay in hospital, use
of medication) will be calculated by the use of reference
unit prices of health care services. The total estimated
costs are rated against change in the level of distress.
Preliminary results
Seven BRCA mutation carriers participated in a GMC in
our pilot study. The overall patient satisfaction with the
GMC was quite promising with an average score of 3.7
(sd = 1.1) on a range of 1-5. More than half of the parti-
cipants (57.1%) would choose a GMC in the future
again. 42.9% experienced support from other patients. A
comparison of the topics, which are discussed during
the GMC according to patients and according to health
professionals showed that according to patients fewer
topics were discussed in the GMC compared to the
number of topics that health care workers reported
(table 1). For instance, all care providers indicated that
the risk for breast cancer and the results of the MRI
and mammography were discussed, while less than half
of the patients mentioned these topics.
Discussion
Several studies showed the advantages of GMCs com-
pared to individual visits. However, for BRCA mutation
carriers the effectiveness has never been studied. Since
GMCs may have disadvantages the effects of GMCs
should carefully be studied.
Most research among other patient groups showed
positive effects on patient and caregiver’s satisfaction.
The participants in the pilot study were also satisfied
about the GMC. This is of importance as a high patient
satisfaction is related to a high quality of life, more com-
pliance and less anxiety and depression [24].
We observed a remarkable difference in the number of
topics discussed during the GMC according to patients
and according to health care workers. This may be
explained by the fact that patients remember only 20-60%
of the information in medical visits and only remember
information that is relevant to them at that moment. The
working memory is limited, therefore only relevant infor-
mation will be processed and stored [59]. It should be
noted that BRCA mutation carriers have a large need for
information [22].
GMCs give the opportunity to provide this information
in a relatively short amount of time, while patients can
make a selection of information, which is particularly rele-
vant for their own situation. Besides, we expect informa-
tion gathered from fellow patients to be better
remembered. At the same time any incorrect information
given by other patients can be corrected immediately by
the health care professional to prevent misunderstandings.
GMCs may fulfill the need for extra attention for
psychosocial related problems, both by health care
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providers and by fellow patients. The possibility for
interaction with other BRCA mutation carriers within a
medical visit is unique.
Of note, despite the widespread implementation of
GMCs in different patient groups, the cost-effectiveness
remains unproven. In the current health care system
cost effectiveness is an important factor to take into
account too.
In conclusion, the aim of our study is to assess the
effectiveness of GMCs for BRCA mutation carriers to
improve empowerment and decrease distress compared
to individual visits. If GMCs prove to be effective and
efficient, implementation of GMCs in regular care for
BRCA mutation carriers will be recommended.
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